Clal Insurance Enterprises Holdings Ltd Has $859.94 Million Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Clal Insurance Enterprises Holdings Ltd lifted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 12.8% in the 4th quarter, Holdings Channel reports. The institutional investor owned 38,962,773 shares of the company’s stock after acquiring an additional 4,418,961 shares during the period. Teva Pharmaceutical Industries comprises about 7.7% of Clal Insurance Enterprises Holdings Ltd’s holdings, making the stock its 3rd biggest position. Clal Insurance Enterprises Holdings Ltd’s holdings in Teva Pharmaceutical Industries were worth $859,935,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. FMR LLC lifted its stake in Teva Pharmaceutical Industries by 49.5% during the third quarter. FMR LLC now owns 62,740,763 shares of the company’s stock worth $1,130,589,000 after purchasing an additional 20,762,226 shares during the period. Lingotto Investment Management LLP lifted its stake in Teva Pharmaceutical Industries by 2.6% during the fourth quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company’s stock worth $599,320,000 after purchasing an additional 688,862 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its stake in Teva Pharmaceutical Industries by 2.2% during the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company’s stock worth $573,822,000 after purchasing an additional 569,412 shares during the period. State Street Corp lifted its stake in Teva Pharmaceutical Industries by 10.0% during the third quarter. State Street Corp now owns 19,500,683 shares of the company’s stock worth $351,402,000 after purchasing an additional 1,778,268 shares during the period. Finally, AustralianSuper Pty Ltd lifted its stake in Teva Pharmaceutical Industries by 16.8% during the fourth quarter. AustralianSuper Pty Ltd now owns 9,222,695 shares of the company’s stock worth $203,268,000 after purchasing an additional 1,329,319 shares during the period. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $16.45 on Friday. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The stock has a market capitalization of $18.64 billion, a P/E ratio of -11.34, a price-to-earnings-growth ratio of 1.44 and a beta of 0.71. The firm has a 50 day moving average of $19.54 and a 200-day moving average of $18.46. Teva Pharmaceutical Industries Limited has a 1 year low of $12.51 and a 1 year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now directly owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.55% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on TEVA. Barclays cut their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. UBS Group cut their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Piper Sandler lifted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. Finally, StockNews.com cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $23.57.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.